Generic placeholder image

Current HIV Research

Author(s): Chaiana Esmeraldino Mendes Marcon, Aline Daiane Schlindwein and Fabiana Schuelter-Trevisol*

DOI: 10.2174/1570162X21666230524141239

DownloadDownload PDF Flyer Cite As
Longitudinal Assessment of Virological Failure and Antiretroviral Drug Resistance among Treatment-naive Subjects Living with HIV

Page: [213 - 219] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Introduction: Human immunodeficiency virus (HIV) infection, the etiological agent of acquired immunodeficiency syndrome (AIDS), is a serious public health issue. Therapeutic measures have been successful in increasing the survival and improving the quality of life. However, some treatment-naive subjects living with HIV present resistance-associated mutations as a result of late diagnosis and/or mutant strain infections. The objective of this study was to identify the virus genotype and assess the antiretroviral resistance profile based on the results of HIV genotyping in treatment-naive subjects living with HIV, after six months of taking antiretroviral therapy.

Methods: This was a prospective cohort study on treatment-naive adults living with HIV attending a specialized outpatient clinic in southern Santa Catarina State, Brazil. The participants were interviewed and had blood samples drawn. The genotypic antiretroviral drug resistance profile was examined in patients with detectable viral loads.

Results: 65 treatment-naive subjects living with HIV were recruited for this study. After six months of taking antiretroviral therapy, resistance-associated mutations were observed in 3 (4.6%) subjects living with HIV.

Conclusion: Subtype C was identified as the circulating subtype in southern Santa Catarina State, and L10V, K103N, A98G, and Y179D were the most common mutations found in treatment-naive subjects.

Graphical Abstract

[1]
Phanuphak N, Gulick RM. HIV treatment and prevention 2019. Curr Opin HIV AIDS 2020; 15(1): 4-12.
[http://dx.doi.org/10.1097/COH.0000000000000588] [PMID: 31658110]
[2]
Palich R. Traitement actuel de l’infection par le VIH. Rev Prat 2021; 71(9): 976-82.
[PMID: 35147313]
[3]
Samandari T, Wiener J, Huang YLA, Hoover KW, Siddiqi AA. Impact of viral suppression among persons with HIV upon estimated HIV incidence between 2010 and 2015 in the United States. PLoS One 2020; 15(10): e0240727.
[http://dx.doi.org/10.1371/journal.pone.0240727] [PMID: 33064746]
[4]
Zazzi M, Hu H, Prosperi M. The global burden of HIV-1 drug resistance in the past 20 years. PeerJ 2018; 6: e4848.
[http://dx.doi.org/10.7717/peerj.4848] [PMID: 29844989]
[5]
Gregson J, Tang M, Ndembi N, et al. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: A multicentre retrospective cohort study. Lancet Infect Dis 2016; 16(5): 565-75.
[http://dx.doi.org/10.1016/S1473-3099(15)00536-8] [PMID: 26831472]
[6]
Bandera A, Gori A, Clerici M, Sironi M. Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance. Curr Opin Pharmacol 2019; 48: 24-32.
[http://dx.doi.org/10.1016/j.coph.2019.03.003] [PMID: 31029861]
[7]
Ferreira ACG, Coelho LE, Grinsztejn E, et al. Transmitted drug resistance in patients with acute/recent HIV infection in Brazil. Braz J Infect Dis 2017; 21(4): 396-401.
[http://dx.doi.org/10.1016/j.bjid.2017.03.013] [PMID: 28539254]
[8]
Blassel L, Zhukova A, Villabona-Arenas CJ, Atkins KE, Hué S, Gascuel O. Drug resistance mutations in HIV: New bioinformatics approaches and challenges. Curr Opin Virol 2021; 51: 56-64.
[http://dx.doi.org/10.1016/j.coviro.2021.09.009] [PMID: 34597873]
[9]
Van Laethem K, Theys K, Vandamme AM. HIV-1 genotypic drug resistance testing: Digging deep, reaching wide? Curr Opin Virol 2015; 14: 16-23.
[http://dx.doi.org/10.1016/j.coviro.2015.06.001] [PMID: 26114581]
[10]
Centro de Genomas. Sao Paulo: Carta Molecular, 2016. Available from: www.centrodegenomas.com.br/arquivo/1/carta _molecular_n25.pdf (Accessed on: 5/10/2016).
[11]
Sullivan PS, Satcher Johnson A, Pembleton ES, et al. Epidemiology of HIV in the USA: Epidemic burden, inequities, contexts, and responses. Lancet 2021; 397(10279): 1095-106.
[http://dx.doi.org/10.1016/S0140-6736(21)00395-0] [PMID: 33617774]
[12]
Mangal TD, Pascom ARP, Vesga JF, Meireles MV, Benzaken AS, Hallett TB. Estimating HIV incidence from surveillance data indicates a second wave of infections in Brazil. Epidemics 2019; 27: 77-85.
[http://dx.doi.org/10.1016/j.epidem.2019.02.002] [PMID: 30772250]
[13]
Ministry of Health. Brasilia: Recommendations for antiretroviral therapy in HIV-infected adults 2008. Available from: http://www.ensp.fiocruz.br/portal-ensp/judicializacao/pdfs/491.pdf (Accessed on: 01/21/2023).
[14]
Mouton JP, Jobanputra N, Tatz G, Cohen K. Serious adverse drug reactions in sub‐Saharan Africa in the era of antiretroviral treatment: A systematic review. Pharmacol Res Perspect 2021; 9(6): e00875.
[http://dx.doi.org/10.1002/prp2.875] [PMID: 34738728]
[15]
Hoosen K, Mosam A, Dlova NC, Grayson W. An update on adverse cutaneous drug reactions in HIV/AIDS. Dermatopathology 2019; 6(2): 111-25.
[http://dx.doi.org/10.1159/000496389] [PMID: 31700852]
[16]
Oumar AA, Dakouo M, Tchibozo A, et al. Antiretroviral-induced adverse drug reactions in HIV-infected patients in Mali: A resource-limited setting experience. Int J Basic Clin Pharmacol 2019; 8(5): 831-6.
[http://dx.doi.org/10.18203/2319-2003.ijbcp20191565] [PMID: 31879663]
[17]
Detsis M, Tsioutis C, Karageorgos SA, Sideroglou T, Hatzakis A, Mylonakis E. Factors associated with HIV Testing and HIV treatment adherence: A systematic review. Curr Pharm Des 2017; 23(18): 2568-78.
[http://dx.doi.org/10.2174/1381612823666170329125820] [PMID: 28356038]
[18]
Murnane PM, Gandhi M, Bacchetti P, et al. Distinct forms of migration and mobility are differentially associated with HIV treatment adherence. AIDS 2022; 36(7): 1021-30.
[http://dx.doi.org/10.1097/QAD.0000000000003213] [PMID: 35652674]
[19]
Cao Z, Li J, Chen H, et al. Effects of HIV-1 genotype on baseline CD4+ cell count and mortality before and after antiretroviral therapy. Sci Rep 2020; 10(1): 15875.
[http://dx.doi.org/10.1038/s41598-020-72701-4] [PMID: 32985559]
[20]
Wood BR, Stekler JD. Baseline HIV genotype drug resistance testing: Is it time for more or less? AIDS 2022; 36(10): 1449-51.
[http://dx.doi.org/10.1097/QAD.0000000000003228] [PMID: 35876702]
[21]
Cao W, Hsieh E, Li T. Optimizing treatment for adults with HIV/AIDS in China: Successes over two decades and remaining challenges. Curr HIV/AIDS Rep 2020; 17(1): 26-34.
[http://dx.doi.org/10.1007/s11904-019-00478-x] [PMID: 31939111]
[22]
Lambert-Niclot S, Grude M, Chaix ML, et al. Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study). J Antimicrob Chemother 2018; 73(8): 2147-51.
[http://dx.doi.org/10.1093/jac/dky142] [PMID: 29718247]
[23]
Hill A, McBride A, Sawyer AW, Clumeck N, Gupta RK. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings. J Infect Dis 2013; 207(S2): S78-84.
[http://dx.doi.org/10.1093/infdis/jit112] [PMID: 23687293]
[24]
Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult hiv infection: 2014 recommendations of the international antiviral society-USA panel. JAMA 2014; 312(4): 410-25.
[http://dx.doi.org/10.1001/jama.2014.8722] [PMID: 25038359]
[25]
Shu Z, Chen Y, Abudureyimu A, et al. Surveillance of HIV-1 drug resistance in Xinjiang: High prevalence of K103N in treatment-naïve individuals. Arch Virol 2018; 163(8): 2111-9.
[http://dx.doi.org/10.1007/s00705-018-3825-7] [PMID: 29633077]
[26]
Barennes H, Guillet S, Limsreng S, et al. Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in Cambodia. PLoS One 2014; 9(8): e105736.
[http://dx.doi.org/10.1371/journal.pone.0105736] [PMID: 25166019]
[27]
Karade SK, Kulkarni SS, Ghate MV, et al. Antiretroviral resistance following immunological monitoring in a resource-limited setting of western India: A cross-sectional study. PLoS One 2017; 12(8): e0181889.
[http://dx.doi.org/10.1371/journal.pone.0181889] [PMID: 28763465]
[28]
Farrokhi M, Moallemi S, Shirkoohi R, et al. Antiretroviral drug resistance mutations among HIV treatment failure patients in Tehran, Iran. Iran J Public Health 2017; 46(9): 1256-64.
[PMID: 29026792]
[29]
Ananworanich J, Sirivichayakul S, Pinyakorn S, et al. High prevalence of transmitted drug resistance in acute HIV-infected Thai men who have sex with men. J Acquir Immune Defic Syndr 2015; 68(4): 481-5.
[http://dx.doi.org/10.1097/QAI.0000000000000502] [PMID: 25559593]
[30]
Dai L, Li N, Wei F, et al. Transmitted antiretroviral drug resistance in the men who have sex with men HIV patient cohort, Beijing, China, 2008-2011. Viral Immunol 2014; 27(8): 392-7.
[http://dx.doi.org/10.1089/vim.2014.0025] [PMID: 25084305]
[31]
Costa CP, Rodrigues JKF, Morais VMS, Andrade CAN, Neves PAF, Lima K. HIV‐1 subtype frequency in Northeast Brazil: A systematic review and meta‐analysis. J Med Virol 2020; 92(12): 3219-29.
[http://dx.doi.org/10.1002/jmv.25842] [PMID: 32266997]